(Corrects typo in day of week in first paragraph)
March 9 (Reuters) – West Pharmaceutical’s chief executive Eric Green said on Monday he plans to retire once the company finds his successor, ending an 11-year run at the helm.
The Pennsylvania-based company said the transition is expected in the second half of 2026 and that an executive search firm has been hired to lead the process.
“After serving 11 years as the Company’s 6th CEO over the past century, it is time for someone else to take over the leadership of West,” Green said in a statement.
Green, who took over as CEO in 2015 and became board chair in 2022, said the move allows him to pursue future board and advisory roles.
During his tenure, the company more than doubled its sales and delivered a total shareholder return of roughly 350%, said Robert Friel, the board’s lead independent director.
West, which makes components and devices used to deliver injectable drugs such as diabetes and obesity treatments, said last month that demand for GLP‑1 therapies will continue to grow in 2026, though at a slower pace than in 2025.
GLP‑1 drugs have become one of the fastest‑growing areas of the pharmaceutical market, requiring the precision delivery parts West supplies.
West also reaffirmed the annual financial forecast it issued in February.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed)
